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Abstract
We focus on themes that are derived from clinical practice and research in the field of genetic diseases of bone
and inborn errors of metabolism but may be of more general interest as they indicate some trends in molecular
medicine as related to pediatrics. Identifying the disease-causing mechanism brings about efficient therapeutic stra-
tegies and discovering the mutant genotype in the near future may become helpful for devising custom-built
molecular responses. At the same time, the transition of therapy from the experimental phase to industrial applica-
tion is difficult as there may be novel roles (and potentially conflicting interests) between physicians, patient orga-
nisations, governmental agencies and the pharmaceutical industry. Awareness of these potential conflicts may help
in recognizing and dealing with these issues.
Nosology and molecular characterization of
genetic disorders
The identification of individual genes responsible for
genetic disorders and the characterization of the muta-
tion spectrum and the pathogenetic mechanism have a
profound influence on the nosology of diseases. This
concept is well illustrated by the group of the so-called
skeletal dysplasias and dysostoses. The great heterogene-
ity in this group of disorders has been first recognized
in the Sixties and led to an expanding classification
based on clinical and radiographic criteria (with the
notable exception of the subgroup of lysosomal storage
diseases that were among the first to be characterized
biochemically). Unfortunately, the somewhat abstruse
denominations of the individual entities and the practi-
cal difficulty of diagnosis based on radiographic features
made the whole field unfriendly to most pediatricians.
Questions pertaining to the legitimacy of the distinction
of such a large number of different disorders were
raised.
In the Eighties and Nineties, several important genes
were identified (COL1A1, COL2A1, FGFR3, DTDST,
COMP), each of which was responsible for a whole vari-
ety of different disorders. The impression arose that per-
haps only a handful of genes with key roles in cartilage
and bone would be responsible for the majority of
skeletal disorders. This notion is correct in the sense
that mutations in these genes are frequent and account
for perhaps one half of all instances of skeletal
dysplasias.
However, the unrelenting stream of new discoveries
shows clearly that the complexity present in the clinical-
radiographic classification does indeed have a biological
substrate: an unexpectedly large number of genes is
involved in skeletal patterning, development and growth,
and mutations in these many genes may result in clini-
cally recognizable disease. These genes show great diver-
sity and reflect a variety of molecular mechanisms; the
micro-cosmos of genetic skeletal disorders reflects the
more general, common themes of genetic mechanisms
at large [1-3].
One gene-one disorder?
One of the most important observations that emerged
from the molecular characterization of genetic skeletal
diseases is the variety of disorders that can be produced
by mutations at a single locus. For example, genes cod-
ing for collagen 1, collagen 2, the sulfate transporter, or
alkaline phosphatase can all be mutated in many differ-
ent ways and give rise to phenotypes that range from
barely discernible to prenatal lethal. Every single one of
these genes is responsible for several “entities” in the
clinical-radiographic classification [1,2]. The difference
in phenotype can be explained by a gradual loss of* Correspondence: asuperti@uniklinik-freiburg.de
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function and can thus be positioned on a more or less
linear gradient [4,5].
Translation of this concept to other fields, such as that
of metabolic diseases, may be instructive. There is no
reason to assume that the same degree of variability will
not be present in most (if not all) enzyme disorders, and
that e.g. methylmalonic acidemia or phenylketonuria
would not be similarly heterogeneous. The variability of
a disorder secondary to mutational heterogeneity at the
responsible locus is a “common theme” in molecular
pediatrics.
Some genes produce more than a linear gradient of
phenotypes. Thus, collagen 1 genes may result in osteo-
genesis imperfecta or an Ehlers-Danlos variant accord-
ing to whether the mutation is in the helical or
propeptide domain; filamin A mutations may produce
either skeletal malformations (the frontometaphyseal
dysplasia-OPDS group) or a neuronal migration disorder
(x-linked heterotopia) according to the portion of the
molecule that is affected [6]; and FGFR2 and FGFR3
mutations may result in quite heterogeneous phenotypes
combining skeletal dysplasias, syndactyly and oligodac-
tyly, synostosis, and a variety of ectodermal findings [7].
The basis of these intriguing observations seems to be
the functional topology of structural molecules and of
receptors, with different functions in different domains
of the protein, as well as the different partners these
molecules may have in different tissues and at different
times during development. Clearly, we must go beyond
a simple one gene-one disorder concept and try to con-
sider the molecular network and the temporal frame-
work around the gene or protein involved.
The recognition of pathways
If mutations in a single gene can produce a range of dif-
ferent diseases, the converse may be true as well - clini-
cally indistinguishable forms of disease can be caused by
mutations in different genes. The simplest form of this
phenomenon occurs when a given molecule has more
than one distinct subunit; thus, osteogenesis imperfecta
can be caused by mutations in either COL1A1 or
COL1A2 genes that encode for the collagen chains
forming type 1 collagen, much as propionic acidemia
can be caused by mutations in either PCCA or PCCB.
Further complexity is present when one phenotype is
caused by mutations in genes that do not form multi-
meric proteins but act either synergistically or sequen-
tially in a biological complex. Infantile Osteopetrosis can
be caused by mutations in a subunit of a proton pump
or in a chloride channel; mutations in carbonic anhy-
drase may produce yet another (milder) form. The
affected biological process (or pathway) is acidification
of the lacunar space delimited by attachment of the
osteoclast to the bone surface, and the phenotype is
similar regardless of which individual step is impaired
[8,9]. Severe chondrodysplasia punctata can result from
at least seven different genetic defects that involve either
the biogenesis of peroxisomes, or the biosynthesis of
cholesterol; it is hoped that the elucidation of the under-
lying pathogenetic processes will shed light on the rela-
tionship between lipid and cholesterol metabolism and
calcification, a process that is ill understood so far but
could reveal some target for therapeutic intervention.
Non-ketotic hyperglycinemia (different components of
the glycine cleavage system) or the type 1 glycogenoses
(glucose 6-phosphatase and coupled transporters;
GSD1a, 1b, 1c) may be cited as counterparts in meta-
bolic disorders.
Yet another possibility is that of pathways sharing a
common final step. The FGFR signaling pathway that is
over-activated in achondroplasia and related disorders
works via the so-called MAP-kinase pathway of intracel-
lular signaling. One step in this pathway is regulated by
cyclic GMP produced by a C-natriuretic peptide recep-
tor with guanylate cyclase activity: this receptor is
mutated in a phenotypically similar disorder, acrome-
somelic dysplasia. Thus, CNP acts on cartilage cells to
antagonize FGFR3; indeed, in an example of “dueling
pathways”, an achondroplasia mouse model was rescued
to normal growth by simultaneous overexpression of
CNP [10]. Understanding pathways and their intersec-
tions will be of growing significance.
Pathways as potential targets of intervention
The benefit of placing a particular disorder in a specific
pathway lies in the recognition of a potential therapeutic
context. The relationship between achondroplasia and
acromesomelic dysplasia has been mentioned above. X-
linked hypophosphatemic rickets (phosphate diabetes) is
a relatively common disorder affecting both males and
females, albeit greater severity is seen in males. Identifi-
cation of the responsible gene, PHEX, initially posed a
riddle as to the function of the encoded protease. Subse-
quent identification of FGF23 as the gene responsible
for autosomal dominant hypophosphatemic rickets and
of FGF23 overproduction in tumor-associated rickets led
to the proposal that FGF23 might be the natural sub-
strate for PHEX, and more generally to the recognition
of a previously unsuspected FGF23-based phosphaturic
regulation mechanism [11]. Pharmacological modulation
of this mechanism is conceivable and would be of
potential therapeutic benefit for hypophosphatemic
ricktes. Genetic disorders have once again revealed phy-
siological mechanisms.
Marfan syndrome is one of the more common genetic
disorders. It is caused, in the vast majority of cases, by
mutations in fibrillin 1, a component of elastic microfi-
bers. While some features of Marfan syndrome such as
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aortic dilatation and lens luxation might be explained
(albeit not simply) by weakness of connective tissue,
overgrowth is difficult to explain in these terms. The
observation of fibrillin acting as a biological reservoir or
buffer for transforming growth factor beta (TGFb) led
to the postulation of a mechanism involving increased
growth induced by reduced TGFb binding by fibrillin
[12]. This concept gained momentum when Marfan syn-
drome variants were found to be caused by mutations in
TGFb receptors. Finally, individuals with diaphyseal dys-
plasia Camurati-Engelmann type (CED) have a body
habitus similar to that observed in Marfan syndrome;
CED is caused by mutations in the TGFb gene that
affect the latency associated peptide function and thus
produce increased TGFb activity. Thus, the three disor-
ders delineate a potent growth-related biological effect
of TGFb. It is tempting to speculate that modulation of
this system may be responsible not only for genetic var-
iations in body length but also in growth impairment
seen so often in chronic diseases in childhood; it is an
obvious potential target for therapeutic intervention.
Recognition of the role of TGFbeta signalling in the
pathogenesis of Marfan syndrome has provided an
unexpected bonus. The relatively old and therefore well-
known drug, losartan, an AT1 syndrome antagonist, is
able to prevent aortic dilatation in a mouse model of
Marfan [13] and preliminary results in patients are
encouraging [14]. Another very rare but fascinating dis-
ease, Hutchinson-Gilford progeria, may be influenced by
treatment with currently available inhibitors of farnesy-
lation [15,16]. Thus, recognition of molecular pathoge-
netic pathways may not only pave the way to the
development of new drugs, but also identify existing
drugs as therapeutic agents.
Approaches to molecular therapy
Many of the examples cited above illustrate how “skele-
tal” disorders can be caused by malfunctioning of struc-
tural molecules but also of metabolic pathways or of
signaling cascades: they are just examples of common
molecular mechanisms. The therapeutic approaches are
similarly heterogeneous. Mouse models are a crucial
step for every single one. Thus, thiol replenishment to
push intracellular production of sulfate is being studied
in a mouse model as a potential therapy for the sulfate
transporter disorders [17]. Enzyme replacement therapy
has been developed for a larger number of disorders
including MPS IV and hypophosphatasia. Pilot studies
in patients with Morquio syndrome and with hypopho-
sphatasia have been conducted; there are good reasons
to assume that the enzyme therapy for Morquio disease,
with a phenotype that arises essentially from cartilage,
will be less successful than that of hypophosphatasia.
The FGFR and CNP signaling pathways can be targeted
by specific agonists (CNP) or by antibodies. Modulation
of the FGF23 phosphaturic system may lead to treat-
ment of hypophosphatemic rickets. Modulation of the
LRP5/dickkopf system may improve bone density in the
Osteoporosis-Pseudoglioma symdrome (OPGS) well as
in other disorders [18]. These exciting prospects make it
easier to accept the fact that gene therapy may still be
years to come.
An even more promising approach derives from the
fact that many key molecules have kinase activity.
FGFRs are tyrosine kinases, while TGFb receptors have
serine/threonine kinase activities. Both classes of mole-
cules have been scrutinized intensively for the identifica-
tion of pharmacological inhibitors. Indeed, inhibition of
the Philadelphia chromosome associated tyrosine kinase
using the specific inhibitor, imatinib (Gleevec or Glivec)
®, is highly efficient in the therapy of leukemia. Imatinib
and the newer tyrosina kinase inhibitors are proving
useful for the treatment of diverse disorders associated
with fibrosis [19,20]. Hopefully, kinase inhibitors of suf-
ficient specificity will be developed in the future and
will be useful in the treatment of genetic disorders asso-
ciated with aberrant kinase signaling.
The potential of chaperones
Molecular therapy for disorders of skeletal growth and
homeostasis may profit from a glance at the neighbour-
ing field of metabolic pediatrics. Here, concepts such as
substrate reduction, product replenishment and selective
metabolic block have been developed and are commonly
applied. One of the most exciting developments in
recent years has been the recognition of chaperone
effects. Mutant proteins are often retained within the
endoplasmic reticulum by a quality control mechanism
that recognizes their imperfect folding. The proteins
involved in accelerating correct protein folding, in guid-
ing the way of correctly folded proteins through the bio-
synthetic steps in the ER and the Golgi, and in retaining
unfolded or misfolded proteins are called “chaperones”.
While these mechanism evolved to prevent the accumu-
lation of misfolded proteins and are beneficial, they may
actually be deleterious when it leads to the degradation
of a protein that, albeit imperfect, has some residual
activity - and the absence of which causes severe
“monogenic” disease. The most common mutation in
CFTR gene, the cystic fibrosis chloride channel, is F508;
CFTR protein bearing this deletion has considerable
residual activity but does not reach the cell membrane,
being retained within the cells and routed for degrada-
tion because of the single missing amino acid. For the
deltaF508 homozygote, delivery of the protein - albeit
imperfect - to the cell surface would be more favourable
than its intracellular degradation. Pharmacological inter-
ventions aimed at rescuing the mutant CFTR and
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allowing its delivery to the cell membrane have been
successful in cell culture models, the most efficient com-
pound being curcumin, a component of widespread and
cheap curry powder [21]. It remains to be seen whether
this approach is effective in vivo.
Cautious optimism is justified in view of other exam-
ples of successful chaperone therapy such as the use of
galactose to enhance residual alpha-galactosidase therapy
in Fabry disease or the use of a substrate analogue to
enhance betagalactosidase activity in GM1 gangliosidosis
[22,23]. Perhaps the most important case yet of success-
ful chaperone therapy is the beneficial effect of tetrahy-
drobiopterin (BH4) administration in phenylketonuria
(PKU). Initially developed to stimulate phenylalanine
hydroxylase (PAH) activity in individuals who have PKU
because of a metabolic defect in the synthesis or regen-
eration of BH4 that is a cofactor of PAH, BH4 has proven
beneficial even in a significant proportion of individuals
who have mutations in the PAH gene itself ("classical”
PKU) [24]. Available data suggest that the mechanism
increasing PAH activity is not a direct stimulation of
activity, but rather a chaperone effect of BH4 leading to
increased production of PAH, perhaps through a bind-
ing-induced stabilization of mutant molecules.
From treatment of disease to molecular therapy
aimed at specific mutations
Research has shown that nonsense mutations cause pre-
mature translational termination and are the reason for
5 to 70% of the individual cases of the majority of inher-
ited diseases [25]. Nonsense-mediated mRNA decay
(NMD) is an mRNA surveillance pathway which ensures
the rapid degradation of mRNA containing premature
translation termination codons (PTCs or nonsense
codons), thereby preventing the accumulation of trun-
cated and potentially harmful proteins. In a disease such
as non-sense mediated cystic fibrosis the increase of
specific protein synthesis from less than 1% to 5% may
have the effect of reducing considerably the severity or
even eliminating the consequences of the disease
[26,27]. PTC124, a drug able to induce ribosomal read-
through of premature but not normal termination
codons, can promote in human and mice cells dystro-
phin production, expressing dystrophin nonsense alleles
[28]. This drug may have considerable scope in clinical
potential for the treatment of several genetic disorders
which have few or even no therapeutic options. This
pioneering approach is one of the first to put persona-
lized medicine to the test where the main focus is not
on the treatment of a disease, but is rather on the treat-
ment of a specific genetic defect.
In this way “readthrough” by means of stop codons is
used for the therapy of non-sense mediated diseases; on
the other hand nonsense-mediated mRNA decay can fail
and be a cause of mental retardation. In fact mutations
in UPF3B, a member of NMD complex, are known to
give rise to syndromic and nonsyndromic mental retar-
dation [29]. In syndromic cases the patients can have
the Lujan-Fryns phenotype or the FG phenotype provid-
ing further evidence for the overlap of these two clinical
conditions.
Another example of personalized molecular medicine
has been investigated by van Deutekon and colleagues
who chose to create a small antisense oligonucleotide
that would enable the cellular machinery to “miss out”
an exon in the mutated Duchenne muscular dystrophy
gene by blocking its inclusion during splicing [30]. The
drug is a small modified nucleic acid named PRO051
that, by blocking the inclusion of exons adjacent to
DMD mutation, restores the reading frame and allows
the production of a form of dystrophin with some resi-
dual function. Although the dystrophin produced under
the splicing modulation with PRO051 is not normal, it
probably retains considerable residual function, as
shown by the condition of patients with clinically milder
Becker’s muscular dystrophy who have similar or identi-
cally modified dystrophins. However there are still var-
ious problems which need to be addressed with regard
to this approach: firstly the optimum number and quan-
tity of injection doses have yet to be satisfactorily estab-
lished, secondly the possible toxic effects are not yet
fully known and are still under investigation, thirdly the
drug being used would only treat a minority of patients
with DMD and other sequences will have to be
researched in order to treat patients with different
mutations. So it is clear that although important steps
have been taken, we are still a long way from achieving
personalized molecular medicine [31].
Transplantation and the quest for the human
stem cell
Bone marrow transplantation has become a therapeutic
possibility for many metabolic diseases, although the
efficiency and risks of the procedure itself and the actual
therapeutic value of successful bone marrow engraft-
ment are variable and still suboptimal and thus, very
careful evaluation is indicated in every single case.
Contrary to what might be expected given the nature
(and the name) of the procedure, the process of BMT
has little or no therapeutic value in most skeletal dyspla-
sias that affect cartilage tissue. This may have to do with
the fact that cartilage is largely avascular. Initial claims
of BMT effectiveness in Osteogenesis Imperfecta remain
to be substantiated. BMT is highly effective in Osteope-
trosis, a disease of bone marrow-derived macrophages.
Hope is that further progress in the selection of stem
cells and perhaps in the conditioning regimes may lead
to an extension of BMT indications.
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Organ transplantation is the mainstay of therapy in
many pediatric renal disorders and in some liver disor-
ders where the indication is malfunction of the organ
itself. In metabolic disorders, the indication to organ
transplantation may derive not only from impairment of
whole organ function but also from impairment of its
metabolic function only, such as in severe organic acide-
mias or in oxalosis. In hepatorenal tyrosinemia, liver dis-
ease results from a profound disturbance in genetic
expression induced by the accumulation of toxic meta-
bolites, and liver transplantation used to be performed
frequently. While the application of a metabolic block-
ade with NBTC delivers dramatic clinical and prognostic
amelioration, the study of liver cell behaviour in the
mouse model of tyrosinemia is yielding fundamental
insights into the regulation of differentiation and prolif-
eration of hepatocytes as well as into the possibility of
using bone marrow-derived cells to obtain viable and
metabolically intact hepatocytes even in the absence of
any stable bone marrow engraftment [32-34]. Prelimin-
ary results indicate that this may be the case even for
renal tubular epithelial cells [35]. Even partial restora-
tion of correct enzyme activity or protein production
might result in clinical cure of several genetic disorders.
The study of cell regeneration and cell fusion in liver
and other tissues carries great promise to result in new
therapeutic options for genetic disorders.
Diseases, physicians, patients, and the
pharmaceutical industry
Ever since the discovery of diseases caused by enzyme
deficiencies, physicians and scientists have tried to
design therapeutic strategies aimed at supplying the
deficient enzyme - with plasma infusion, with cell trans-
plantation, with bone marrow transplantation. Besides
bone marrow transplantation, enzyme replacement ther-
apy (ERT) for b-glucocerebrosidase deficiency (Gaucher
disease) was the first ERT to show clinical utility. ERT
for Gaucher disease has been developed at the National
Institutes of Health [36] and originally licensed to the
company, Genzyme, under the Orphan Drug Act. Mar-
keting of the enzyme preparation has proven extremely
successful. Almost twenty years later, more ERT pro-
ducts are in routine use, and others are close to their
introduction to the market. Genzyme has become one
of the financially most successful biotechnology com-
pany ever, its stock prices having increased by approxi-
mately 600% from 1992 to 2005 [37,38]. Conversely,
national medical systems are in no better health now
than then.
The existence of a strong pharmaceutical industry is
of great importance, and research carried out by indus-
try is significant and beneficial. However, in the case of
Alglucerase®, the high price of the preparation
immediately raised questions concerning public vs. pri-
vate contributions in the development of that therapy
[39]. Unfortunately, the hope that was originally held in
recombinant DNA production technologies does not
seem to have been justified, as the price of Gaucher
treatment with “recombinant” enzyme is higher, not
lower, than that of the placenta-derived enzyme. Thus,
the questions concerning the payment for extremely
expensive treatments of rare disorders raised in 1992 are
still unanswered; specifically, the cost of life years, even
after adjustment for quality of life, is much higher than
that of all other available drugs. The long-term implica-
tions of highly expensive treatments for rare disorders
remain a matter of debate [40].
Another observation worthy of reflection is that upon
introduction to the market of ERT for MPS VI, the pro-
ducing company distributed publicity items (brochures
and bags) that explicitly questioned whether patients
with MPS VI had been recognized and diagnosed. A
similar strategy, though not as explicit, was used years
earlier when the Gaucher ERT had been marketed in
Europe: the warning that physicians might have missed
the diagnosis was expressed in sponsored articles both
in the medical and in the lay press. If the traditional
paradigm was patients and physicians in search of a
treatment, this was an inversion - a lucrative treatment
in search of patients, and pressure being put on physi-
cians not to miss them.
Similar strategies have been enacted by the growth
hormone industry. More and more indications, some of
which of questionable significance, have been recognized
and - most importantly - been pushed through approba-
tion by governmental agencies to obtain reimbursement
by medical insurances. While growth hormone therapy
for indications other than true growth hormone defi-
ciencies may bring benefit to affected individuals, the
high cost of such therapies means that significant
amounts of money are diverted from other causes that
are potentially of similar or even higher benefit, but for
which there is no lobby; seen from inside the pediatric
system, it is clear that the recognition of additional indi-
cations for GH therapy is driven more by the growth
hormone industry than by pediatricians or patients. In
Germany, industries producing growth hormone have
formed a “consortium” with the declared aim of pro-
moting research and dissemination of results; de facto, it
seems clear that these industries are forming a trust to
prevent competition and thus to prevent a lower pricing
of GH treatment. Interestingly, advertising by these
industries suggests that “short stature is not unavoid-
able” and thus aims at a very broad audience, not just
physicians dealing with children with rare conditions.
In conclusion, a situation is developing in which the
pharmaceutical industry is putting pressure on
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governmental agencies to grant recognition of drugs and
of treatment indications, and secondarily put pressure
on physicians “not to miss” patients with these treatable
conditions. Often, collaboration of physicians is obtained
by allocation of small financial rewards for “observation”
of patients. While this is not bad per se, the high price
of these drugs leads to a situation where treatment prio-
rities are set by the industry and not by responsible phy-
sicians. The stronger marketing strategies of
pharmaceutical industry may be favoured by the Orphan
Drug Act that grants monopoly and tends to block the
development of competition. We can hope that industry
will continue to fulfill its role in the development and
marketing of new treatments but that conditions of
monopoly over individual drugs will not be the cause of
financial restrictions and social inequalities.
Roles of self-help groups and parents
organizations
Patients’ organizations and - in the case of pediatrics -
parental organizations ("self-help groups”) are emerging
as the new players in the developing relationships on
the health market. The primordial relationship between
the patient and the physician first had to take the third
partner into account - the health insurer as the payer.
Meanwhile, industry is proposing itself as the fourth
partner - traditionally wooing the physician in order to
obtain favourable prescription of one or the other profit-
able drug, but recently - as in the case of ERT - with a
new preposterousness.
It is not only acceptable, but also fair and desirable
that individuals affected by severe and/or rare disease
join forces in order to share experiences, offer mutual
assistance, and act together to put forward their agenda.
Potential areas of activity of patients’ organisations are
(among others) the exchange of information concerning
treatment modalities and medical centers through meet-
ings and brochures, the organization of cooperatives to
buy or import medical or dietary supply at favourable
price, the support of research, the counseling of medical
researchers as to what are the objectives for clinical and
basic research, the support of those research projects by
helping in recruiting patient cohorts or in fundraising,
and political lobbying to obtain favourable legislation.
The efficiency of patients’ organizations can be so high
that patients may quickly obtain a degree of competence
in “their” disorder ("empowerment”) that the average
physician may find much more difficult to obtain; thus,
the knowledge advantage that used to play in favour of
the physician can be inverted; this can also occur
through the internet, although on the latter, information
is usually much less organized and the wealth of infor-
mation is not matched by quality and structured presen-
tation. Examples are known where patients’
organisations have exerted pressure on individual
patients and families recommending one treatment over
another and even one physician over another. Industry
has recognized the growing power of such organizations,
with the result that more and more sponsoring is taking
place directly between industry and patients’ organiza-
tions, bypassing the physicians who should decide upon
the indications to treat.
How is the relationship between pediatricians and par-
ental organizations going to evolve? Clearly, parents’
organizations are here to stay; they can potentially
assume a highly beneficial role in the health care system,
taking on responsibility and providing assistance that
the physician is unable to provide because of financial
and time constraints. However, a deontological code of
honour should be adopted in order to ensure that
patients’ (and parents’) associations do maintain their
own independence and at the same time allow indepen-
dence of individual patients and of physicians.
Conclusions
Aren’t our times interesting? New molecular insights are
flowing continuously and providing us with new con-
cepts. Leads from these exciting results can be taken up
by cell biologists and pharmacologists to develop new
treatments. However, the scenario around us is moving;
the partners we have to rely upon as physicians - the
medical insurers and the pharmaceutical industry - are
changing, a change dictated by increasing economical
pressure that threatens the alliance with physicians; and
the biological progress may not benefit the patients as
quickly and directly as we might hope, or create new
inequalities in the access to therapy. The task of devel-
oping new diagnostic procedures and effective treat-
ments is formidable, but the task of bringing these to
the market in a way that is socially sustainable is just as
important. Our most important partner, the patient (for
pediatricians, the sick child and its parents and advo-
cates), is also changing; he is growing up and demand-
ing a more mature relationship with the physician as a
partner more than as a leader. In this perspective, the
health players - patients and their organisations, physi-
cians, insurers and the pharmaceutical industry - will
have to agree on what can be termed “sustainable devel-
opment” in a nation’s health system. Pediatricians
should be aware of these potential conflicts and take a
proactive attitude or otherwise risk becoming more and
more debased to care providers in a system that is
designed and maintained by others.
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